RU2535033C2 - Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида - Google Patents
Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида Download PDFInfo
- Publication number
- RU2535033C2 RU2535033C2 RU2010133045/15A RU2010133045A RU2535033C2 RU 2535033 C2 RU2535033 C2 RU 2535033C2 RU 2010133045/15 A RU2010133045/15 A RU 2010133045/15A RU 2010133045 A RU2010133045 A RU 2010133045A RU 2535033 C2 RU2535033 C2 RU 2535033C2
- Authority
- RU
- Russia
- Prior art keywords
- antibodies
- hiv
- pharmaceutical composition
- activated potentiated
- cells
- Prior art date
Links
- 208000031886 HIV Infections Diseases 0.000 title claims abstract description 14
- 208000037357 HIV infectious disease Diseases 0.000 title claims abstract description 14
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims description 15
- 239000003814 drug Substances 0.000 title abstract description 32
- 229940124597 therapeutic agent Drugs 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title description 13
- 201000010099 disease Diseases 0.000 title description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 9
- 238000011282 treatment Methods 0.000 title description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 230000000798 anti-retroviral effect Effects 0.000 claims abstract description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 6
- 230000000694 effects Effects 0.000 claims abstract description 5
- 230000005714 functional activity Effects 0.000 claims abstract description 5
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 3
- 238000010790 dilution Methods 0.000 claims description 37
- 239000012895 dilution Substances 0.000 claims description 37
- 239000000243 solution Substances 0.000 claims description 37
- 239000000427 antigen Substances 0.000 claims description 35
- 108091007433 antigens Proteins 0.000 claims description 35
- 102000036639 antigens Human genes 0.000 claims description 35
- 210000004027 cell Anatomy 0.000 claims description 31
- 210000000987 immune system Anatomy 0.000 claims description 23
- 239000011159 matrix material Substances 0.000 claims description 20
- 239000012528 membrane Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 238000005516 engineering process Methods 0.000 claims description 11
- 230000001632 homeopathic effect Effects 0.000 claims description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 230000009471 action Effects 0.000 claims description 7
- 230000007935 neutral effect Effects 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 102000008070 Interferon-gamma Human genes 0.000 claims description 4
- 108010074328 Interferon-gamma Proteins 0.000 claims description 4
- 229940044627 gamma-interferon Drugs 0.000 claims description 4
- 108010041397 CD4 Antigens Proteins 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 239000007909 solid dosage form Substances 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 238000013207 serial dilution Methods 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 34
- 229940079593 drug Drugs 0.000 description 24
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 17
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 17
- 230000010076 replication Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 7
- 229960002555 zidovudine Drugs 0.000 description 7
- 208000030507 AIDS Diseases 0.000 description 6
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000007865 diluting Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 102000055277 human IL2 Human genes 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 108010032795 CD8 receptor Proteins 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 206010043417 Therapeutic response unexpected Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Priority Applications (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2010133045/15A RU2535033C2 (ru) | 2010-08-06 | 2010-08-06 | Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида |
| DE112011102649T DE112011102649T5 (de) | 2010-08-06 | 2011-07-15 | Medikament und Verfahren zur Prävention einer HIV-Kontamination, Prävention und Behandlung von Krankheiten, die durch HIV verursacht werden, und von mit HIV zusammenhängen-den Krankheiten, einschließlich AIDS |
| GB1303983.9A GB2498276B (en) | 2010-08-06 | 2011-07-15 | Medicinal agent and mode of prevention of HIV contamination, prevention and treatment of diseases caused by HIV and HIV-associated diseases including AIDS. |
| CN2011800403882A CN103209705A (zh) | 2010-08-06 | 2011-07-15 | 预防hiv感染以及对由hiv引起的疾病和hiv相关疾病、包括aids进行预防和治疗的药剂和方法 |
| UAA201300101A UA112747C2 (uk) | 2010-08-06 | 2011-07-15 | Лікарський засіб і спосіб профілактики інфікування віл, профілактики і лікування захворювань, що викликаються віл або асоційовані з віл, у тому числі сніду |
| EA201300136A EA030411B1 (ru) | 2010-08-06 | 2011-07-15 | Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида |
| US13/814,659 US20130224219A1 (en) | 2010-08-06 | 2011-07-15 | Drug and method for the prophylaxis of hiv infection and for the prophylaxis and treatment of diseases caused by or associated with hiv, including aids |
| CA2807540A CA2807540A1 (en) | 2010-08-06 | 2011-07-15 | Medicinal agent and mode of prevention of hiv contamination, prevention and treatment of diseases caused by hiv and hiv-associated diseases including aids |
| JP2013523123A JP2013538195A (ja) | 2010-08-06 | 2011-07-15 | Ｈｉｖ汚染の予防、ａｉｄｓを含むｈｉｖによって引き起こされる疾患及びｈｉｖに関連する疾患の予防及び治療のための医薬及び方法 |
| NZ606992A NZ606992A (en) | 2010-08-06 | 2011-07-15 | Drug and method for the prophylaxis of hiv infection and for the prophylaxis and treatment of diseases caused by or associated with hiv, including aids |
| EP11814861.8A EP2601967A4 (en) | 2010-08-06 | 2011-07-15 | MEDICINE FOR PREVENTING AND TREATING HIV-RELATED OR HIV-RELATED DISEASES, INCLUDING AIDS |
| ES201390021A ES2555557R1 (es) | 2010-08-06 | 2011-07-15 | Fármaco y uso para preparar un medicamento destinado a la prevención de la infección del VIH y al tratamiento de enfermedades causadas por el VIH, incluido el SIDA |
| AU2011286486A AU2011286486B9 (en) | 2010-08-06 | 2011-07-15 | Drug and method for the prophylaxis of HIV infection and for the prophylaxis and treatment of diseases caused by or associated with HIV, including aids |
| PCT/RU2011/000523 WO2012018284A1 (ru) | 2010-08-06 | 2011-07-15 | Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2010133045/15A RU2535033C2 (ru) | 2010-08-06 | 2010-08-06 | Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010133045A RU2010133045A (ru) | 2012-02-20 |
| RU2535033C2 true RU2535033C2 (ru) | 2014-12-10 |
Family
ID=45559675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010133045/15A RU2535033C2 (ru) | 2010-08-06 | 2010-08-06 | Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20130224219A1 (enExample) |
| EP (1) | EP2601967A4 (enExample) |
| JP (1) | JP2013538195A (enExample) |
| CN (1) | CN103209705A (enExample) |
| AU (1) | AU2011286486B9 (enExample) |
| CA (1) | CA2807540A1 (enExample) |
| DE (1) | DE112011102649T5 (enExample) |
| EA (1) | EA030411B1 (enExample) |
| ES (1) | ES2555557R1 (enExample) |
| GB (1) | GB2498276B (enExample) |
| NZ (1) | NZ606992A (enExample) |
| RU (1) | RU2535033C2 (enExample) |
| UA (1) | UA112747C2 (enExample) |
| WO (1) | WO2012018284A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2181297C2 (ru) | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| RU2309732C1 (ru) * | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
| MX2013000543A (es) | 2010-07-15 | 2013-10-28 | Oleg Iliich Epshtein | Un metodo para aumentar el efecto de una forma activa potenciada de un anticuerpo. |
| FR2962652A1 (fr) | 2010-07-15 | 2012-01-20 | Oleg Iliich Epshtein | Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees a des maladies neurodegeneratives |
| PH12013500144A1 (en) | 2010-07-21 | 2018-03-21 | Oleg Iliich Epshtein | A method of treating attention deficit hyperactivity disorder |
| WO2014116789A1 (en) * | 2013-01-25 | 2014-07-31 | Thymon, Llc | Immunogenic and prophylactic compositions, methods of making same, and method for treating and preventing tnf-mediated disease and hiv-1 infection |
| KR101759687B1 (ko) | 2013-01-25 | 2017-07-19 | 타이몬, 엘엘씨 | 순환하는 생물활성 가용성 tnf의 선택적 감소를 위한 조성물 및 tnf-매개 질환의 치료 방법 |
| RU2013111961A (ru) | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
| RU2013111962A (ru) | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000035446A (ko) * | 1998-11-13 | 2000-06-26 | 고니시 진우에몬 | 세포접착분자 발현억제제 |
| RU2192888C1 (ru) * | 2001-02-15 | 2002-11-20 | Эпштейн Олег Ильич | Лекарственное средство и способ лечения патологического синдрома |
| RU2008110058A (ru) * | 2005-08-15 | 2009-09-27 | Арана Терапьютикс Лимитед (Au) | Химерные антитела с областями приматов нового света |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4236069A1 (de) * | 1992-10-26 | 1994-04-28 | Werner Dr Bergmann | Arzneimittel, insbesondere für orale Einnahme |
| AU2275395A (en) * | 1994-03-31 | 1995-10-23 | Biomedical Explorations, Llc | Therapeutic homeopathic dilutions of growth factors and methods of their use |
| US20030228310A1 (en) * | 1996-12-23 | 2003-12-11 | Advanced Biotherapy, Inc. | Treatment of skin diseases |
| US6090388A (en) * | 1998-06-20 | 2000-07-18 | United Biomedical Inc. | Peptide composition for prevention and treatment of HIV infection and immune disorders |
| RU2181297C2 (ru) * | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| RU2195317C1 (ru) * | 2001-04-18 | 2002-12-27 | Эпштейн Олег Ильич | Способ коррекции патологических иммунных реакций и лекарственное средство |
| RU2001134982A (ru) * | 2001-12-26 | 2004-02-20 | Олег Ильич Эпштейн | Способ коррекции иммунного ответа и лекарственное средство |
| RU2201255C1 (ru) * | 2001-12-26 | 2003-03-27 | Эпштейн Олег Ильич | Лекарственное средство и способ регуляции сосудистого тонуса |
| RU2205025C1 (ru) * | 2001-12-26 | 2003-05-27 | Гольдберг Евгений Данилович | Способ коррекции иммунного ответа и лекарственное средство |
| UA76640C2 (uk) * | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб |
| DE602007006429D1 (de) * | 2006-02-10 | 2010-06-24 | Zymogenetics Inc | Lösliches il-17rcx4 und verfahren zu dessen anwendung bei entzündungen |
| RU2309732C1 (ru) * | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
| MX345039B (es) * | 2008-06-25 | 2017-01-16 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles que inhiben el tnfa. |
| CZ2013159A3 (cs) * | 2010-08-06 | 2013-06-12 | Iliich Epshtein@Oleg | Kombinovaná farmaceutická kompozice a zpusoby lécby a prevence infekcních chorob |
-
2010
- 2010-08-06 RU RU2010133045/15A patent/RU2535033C2/ru not_active IP Right Cessation
-
2011
- 2011-07-15 US US13/814,659 patent/US20130224219A1/en not_active Abandoned
- 2011-07-15 ES ES201390021A patent/ES2555557R1/es active Pending
- 2011-07-15 EP EP11814861.8A patent/EP2601967A4/en not_active Ceased
- 2011-07-15 UA UAA201300101A patent/UA112747C2/uk unknown
- 2011-07-15 WO PCT/RU2011/000523 patent/WO2012018284A1/ru not_active Ceased
- 2011-07-15 GB GB1303983.9A patent/GB2498276B/en not_active Expired - Fee Related
- 2011-07-15 CA CA2807540A patent/CA2807540A1/en not_active Abandoned
- 2011-07-15 JP JP2013523123A patent/JP2013538195A/ja active Pending
- 2011-07-15 EA EA201300136A patent/EA030411B1/ru not_active IP Right Cessation
- 2011-07-15 DE DE112011102649T patent/DE112011102649T5/de not_active Withdrawn
- 2011-07-15 NZ NZ606992A patent/NZ606992A/en not_active IP Right Cessation
- 2011-07-15 CN CN2011800403882A patent/CN103209705A/zh active Pending
- 2011-07-15 AU AU2011286486A patent/AU2011286486B9/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000035446A (ko) * | 1998-11-13 | 2000-06-26 | 고니시 진우에몬 | 세포접착분자 발현억제제 |
| RU2192888C1 (ru) * | 2001-02-15 | 2002-11-20 | Эпштейн Олег Ильич | Лекарственное средство и способ лечения патологического синдрома |
| RU2008110058A (ru) * | 2005-08-15 | 2009-09-27 | Арана Терапьютикс Лимитед (Au) | Химерные антитела с областями приматов нового света |
Non-Patent Citations (1)
| Title |
|---|
| ВАСИЛЬЕВ А.Н. и др. "Применение сверхмалых доз антител к гамма-интерферону в лечении и профилактике вирусных инфекций". Антибиотики и химиотерапия, 2008;53:32-35. PETROVAY F. et al. Chronic infections and histamine,CRP and IL-6 levels after percutaneous transluminal coronary angioplasty" Inflam Res 2007 Sep;56(9):362-7, реферат, [найдено 22.08.2011], найдено из PubMed PMID:17878998. * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2555557A2 (es) | 2016-01-04 |
| AU2011286486A2 (en) | 2013-05-02 |
| DE112011102649T5 (de) | 2013-06-20 |
| EA030411B1 (ru) | 2018-08-31 |
| EP2601967A4 (en) | 2014-05-07 |
| CN103209705A (zh) | 2013-07-17 |
| JP2013538195A (ja) | 2013-10-10 |
| GB2498276A (en) | 2013-07-10 |
| NZ606992A (en) | 2016-03-31 |
| CA2807540A1 (en) | 2012-02-09 |
| WO2012018284A1 (ru) | 2012-02-09 |
| US20130224219A1 (en) | 2013-08-29 |
| EA201300136A1 (ru) | 2013-09-30 |
| GB201303983D0 (en) | 2013-04-17 |
| AU2011286486B2 (en) | 2017-02-02 |
| EP2601967A1 (en) | 2013-06-12 |
| GB2498276B (en) | 2018-05-23 |
| AU2011286486B9 (en) | 2017-02-23 |
| RU2010133045A (ru) | 2012-02-20 |
| AU2011286486A1 (en) | 2013-03-28 |
| UA112747C2 (uk) | 2016-10-25 |
| ES2555557R1 (es) | 2016-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2535033C2 (ru) | Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида | |
| RU2535034C2 (ru) | Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида | |
| AU2011287292B2 (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| RU2577299C2 (ru) | Способ лечения инфекционных заболеваний и комплексное лекарственное средство для лечения инфекционных заболеваний | |
| RU2517084C2 (ru) | Способ и средство для ингибирования продукции или усиления элиминации белка р24 | |
| US20120263725A1 (en) | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV | |
| RU2521392C2 (ru) | Комплексное лекарственное средство для лечения вирусных заболеваний и способ лечения вирусных заболеваний | |
| RU2517085C2 (ru) | Комплексное лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида | |
| RU2502521C2 (ru) | Комплексное лекарственное средство для лечения бактериальных инфекций и способ лечения бактериальных инфекций | |
| RU2579262C1 (ru) | Лекарственное средство для лечения инфекционных заболеваний | |
| RU2441023C1 (ru) | Лекарственное средство для лечения рассеянного склероза и способ лечения рассеянного склероза | |
| RU2516931C2 (ru) | Способ и композиция для профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида | |
| RU2519862C2 (ru) | Комплексное лекарственное средство и способ профилактики и лечения инфекционных вирусных заболеваний | |
| EA032021B1 (ru) | Фармацевтическая композиция и способ лечения и профилактики заболеваний, вызванных и/или ассоциированных с вич | |
| CA2807529A1 (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20180807 |